AMENDED CLAIMS

[(received by the International Bureau on 11 May 2005 (11.05.05); original claims 1-2 amended; remaining claims unchanged (3 pages)]

1. A compound of the formula

wherein:

each X is independently CH_2 , C(O), N, O, S, S(O), $S(O)_2$, or is a bond; and each of R_1 to R_5 is independently a bond or is selected from the group consisting of:

hydrogen;

halogen;

azide;

an R group defined as C1 to C8 alkyl or alkenyl, anyl or heteroaryl optionally further substituted by:

an alkoxy, aryl, heteroaryl or aryloxy group;

-COOH, -S(O)₂OH, phosphate, carboxylate or tetrazolyl;

 $-S(O)_2OH_2$ $-S(O)OH_3$ $-S(O)R_3$, $S(O)_2R_3$ $-S(O)_2NH_2$, $-S(O)_2OR_3$

-S(O)OR;

-C(O)R;

phosphate, carboxylate or tetrazolyl;

an unsubstituted or substituted heterocylic group, wherein the substitution is by:

an alkyl or aryl group, -CH2NHC(O)R, -CH2N(C(O)R)2, -CH2OR,

wherein R is as defined above;

connected to a different R_1 to R_5 to form a new cyclic group;

a substructure based upon a group of the following formula:

wherein:

Y is H, R or -C(O)R, wherein R is as defined above;

AMENDED SHEET (ARTICLE 19)

at least one, but not more than two of R_7 to R_{11} is independently a structure according to formula I; or

a structure comprising a second unit according to formula II linked via a "Y" group wherein each unit is independently substituted by R_7 to R_{10} ; with the provisos that:

when R_1 is $-CH_3$, $-S(O)_2OH$ or -H at least one of R_2 to R_5 is not -H or $-S(O)_2OH$;

when a substructure of type II is not present and none of R_1 - R_5 form an anhydro bridge, no more than two of R_1 - R_5 are -S(O)₂OH and the stereochemistry of I is not gluco or galacto;

- 2. A compound according to claim 1, wherein said compound is PG2024, PG2037, PG2173, PG2198, as hereinbefore described.
- 3. A compound according to claim 1, wherein said compound is any one of the compounds of Tables 1-4 of the description.
- 4. A pharmaceutical or veterinary composition for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection, which composition comprises at least one compound according to claim 1 together with a pharmaceutically or veterinarially acceptable carrier or diluent for said at least one compound.
- 5. The composition according to claim 4 which further includes a pharmaceutically or veterinarially acceptable excipient, buffer, stabiliser, isotonicising agent, preservative or antioxidant.
- 6. The composition according to claim 4, wherein said compound is present therein as an ester, a free acid or base, a hydrate, or a prodrug.
- 7. Use of a compound according to claim 1 in the manufacture of a medicament for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection.
- 8. The use according to claim 7, wherein said mammalian subject is a human subject.
- 9. A method for the prevention or treatment in a mammalian subject of a disorder resulting from angiogenesis, metastasis, inflammation, coagulation, thrombosis, and/or microbial infection, which method comprises administering to the subject an effective amount of at least one compound according to claim 1, or a composition comprising said at least one compound.

- 10. The method according to claim 9 wherein said mammalian subject is a human subject.
- 11. The method according to claim 9, wherein said disorder resulting from angiogenesis is a proliferative retinopathy or angiogenesis resulting from the growth of a solid tumour.
- 12. The method according to claim 9, wherein said disorder resulting from inflammation is rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, allograft rejection or chronic asthma.
- 13. The method according to claim 9, wherein said disorder resulting from coagulation and/or thrombosis is deep venous thrombosis, pulmonary embolism, thrombotic stroke, peripheral arterial thrombosis, unstable angina or myocardial infarction.
- 14. The method according to claim 9, wherein said disorder resulting from viral infection is Herpes Simplex.